CD40 and myasthenia gravis: The majority of CD40 therapies used in the treatment of autoimmune and neuroinflammatory disorders such as MG, MS, and ALS, exist in the form of antagonistic monoclonal antibodies against CD40 or CD40L and are administered either as a single agent or in combination with other antibodies, chemotherapeutic agents, and/or corticosteroids (Table 1).